Table of Contents
Table of Contents
List of Tables
List of Figures
IMPAX Laboratories, Inc. Snapshot
IMPAX Laboratories, Inc. Overview
Key Information
Key Facts
IMPAX Laboratories, Inc. - Research and Development Overview
Key Therapeutic Areas
IMPAX Laboratories, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
IMPAX Laboratories, Inc. - Pipeline Products Glance
IMPAX Laboratories, Inc. - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
IMPAX Laboratories, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
IMPAX Laboratories, Inc. - Drug Profiles
IPX056
Product Description
Mechanism of Action
R&D Progress
IPX066
Product Description
Mechanism of Action
R&D Progress
IPX159
Product Description
Mechanism of Action
R&D Progress
IMPAX Laboratories, Inc. - Pipeline Products by Route of Administration
IMPAX Laboratories, Inc. - Pipeline Products By Mechanism of Action
IMPAX Laboratories, Inc. - Recent Pipeline Updates
IMPAX Laboratories, Inc. - Dormant Projects
IMPAX Laboratories, Inc. - Company Statement
IMPAX Laboratories, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
IMPAX Laboratories, Inc., Recent Developments
IMPAX Laboratories, Inc.- Press Release
Apr 18, 2012: Impax To Presents Data From ASCEND-PD Phase III Study Of IPX066 At American Academy Of Neurology Conference
Feb 23, 2012: FDA Accepts NDA Filing For IPX066 For Treatment Of Idiopathic Parkinson's Disease
Dec 02, 2009: Impax Laboratories Acquires Rights to Abbreviated New Drug Applications
Oct 27, 2009: Impax Pharmaceuticals Commences Phase III trial Of IPX066 Drug In PD patients
Oct 07, 2009: Impax Laboratories Settles Pending Litigation for FLOMAX
Oct 05, 2009: Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX 0.4mg Capsules
Oct 01, 2009: Impax Starts Shipment Of Generic Adderall XR Capsules
Sep 23, 2009: Impax Pharmaceuticals Presents Positive Results Of Phase II Trial Of IPX066
Sep 21, 2009: Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson's Disease
Aug 05, 2009: Impax Laboratories Receives Final FDA Approval for Generic Depakote Extended-Release 500mg Tablets
Jun 08, 2009: Impax Pharmaceuticals Presents Phase II Data at 13th International Congress Of Parkinson's Disease And Movement Disorders
May 19, 2009: Impax Receives FDA Approval for Generic Precose Tablets, 25 mg, 50 mg and 100 mg
May 06, 2009: Impax Receives Final FDA Approval for Generic Depakote Extended-Release 250mg Tablets
Apr 22, 2009: Impax Pharmaceuticals Presents Positive Achievements On Its Two Leading Brand Product Candidates Including IPX066
Apr 20, 2009: Impax Pharmaceuticals Commences A Phase III Trial Of IPX066
Apr 20, 2009: Impax Pharmaceuticals Reports Positive Achievements On Its Leading Brand Product Candidate IPX056
Mar 20, 2009: Impax Confirms Patent Lawsuit Relating to Doryx Tablets 150 mg
Mar 17, 2009: Impax Confirms ANDA Filing For Doryx Tablets 150mg
Jan 26, 2009: IMPAX Receives Final FDA Approval For Omeprazole 40 Mg Capsules
Financial Deals Landscape
IMPAX Laboratories, Inc., Deals Summary
IMPAX Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma
Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs
Partnerships
Impax Labs Enters Into Development And Distribution Agreement With Tolmar
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps
Impax Labs Enters Into Co-Development Agreement With Perrigo
IGI Labs Enters Into Co-Development Agreement With IMPAX Labs
IMPAX Labs Amends Co-Promotion Agreement With Wyeth
IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth
Medicis Pharma Enters Into An Agreement With IMPAX Labs
Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs
Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol
IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR
Licensing Agreements
Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig
GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066
IMPAX Labs Enters Into Licensing Agreement With Endo Pharma
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs
Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs
Wyeth Enters Into Agreement With IMPAX
Impax Labs Enters Into Licensing Agreement With Wyeth
Impax Labs Enters Into Licensing Agreement With Purdue Pharma
Impax Labs Enters Into Licensing Agreement With DAVA Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
IMPAX Laboratories, Inc., Key Information
IMPAX Laboratories, Inc., Key Facts
IMPAX Laboratories, Inc. - Pipeline by Indication, 2012
IMPAX Laboratories, Inc. - Pipeline by Stage of Development, 2012
IMPAX Laboratories, Inc. - Monotherapy Products in Pipeline, 2012
IMPAX Laboratories, Inc. - Filed, 2012
IMPAX Laboratories, Inc. - Phase II, 2012
IMPAX Laboratories, Inc. - Pipeline By Route of Administration, 2012
IMPAX Laboratories, Inc. - Pipeline Products By Mechanism of Action, 2012
IMPAX Laboratories, Inc. - Recent Pipeline Updates, 2012
IMPAX Laboratories, Inc. - Dormant Developmental Projects,2012
IMPAX Laboratories, Inc., Other Locations
IMPAX Laboratories, Inc., Subsidiaries
IMPAX Laboratories, Inc., Deals Summary
Impax Labs Acquires Abbreviated New Drug Applications Rights From Watson Pharma
Impax Labs Acquires ANDA Rights Of Dronabinol From Cobalt Labs
Impax Labs Enters Into Development And Distribution Agreement With Tolmar
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps
Impax Labs Enters Into Co-Development Agreement With Perrigo
IGI Labs Enters Into Co-Development Agreement With IMPAX Labs
IMPAX Labs Amends Co-Promotion Agreement With Wyeth
IMPAX Labs Enters Into Co-Promotion Agreement With Wyeth
Medicis Pharma Enters Into An Agreement With IMPAX Labs
Intec Pharma Enters Into Co-Development Agreement With IMPAX Labs
Impax Labs Enters Into Co-Promotion Agreement With Shire For Carbatrol
IMPAX Labs Enters Into Co-Marketing Agreement With Shire For Adderall XR
Impax Pharma Enters Into Licensing Agreement With AstraZeneca For Zomig
GlaxoSmithKline Enters Into Licensing Agreement With Impax Pharma For IPX066
IMPAX Labs Enters Into Licensing Agreement With Endo Pharma
Endo Pharma And Penwest Pharma Enter Into Licensing Agreement With Impax Labs
Medicis Pharma Enters Into Licensing Agreement With IMPAX Labs
Wyeth Enters Into Agreement With IMPAX
Impax Labs Enters Into Licensing Agreement With Wyeth
Impax Labs Enters Into Licensing Agreement With Purdue Pharma
Impax Labs Enters Into Licensing Agreement With DAVA Pharma
List of Figures
IMPAX Laboratories, Inc. - Pipeline by Indication, 2012
IMPAX Laboratories, Inc. - Pipeline by Stage of Development, 2012
IMPAX Laboratories, Inc. - Monotherapy Products in Pipeline, 2012
IMPAX Laboratories, Inc. - Pipeline Products By Mechanism of Action, 2012 19